Individual drug sampling does not supplant the need for head-to-head trials in dermatology - 24/04/13
See related commentary on page 1053
Abstract |
A growing body of evidence has highlighted several risks and benefits associated with in-office sampling of prescription medications. While use-testing dermatologic medications from a sample closet may benefit some patients, it seems that the stunning lack of head-to-head trials comparing therapeutic options is a much larger and more important impediment to our determination of when the increased cost of newer agents is justified by superior efficacy, safety, or tolerability. If physicians are to retain the critical autonomy to make independent prescribing decisions in concert with our individual patients, we must take responsibility to call for and generate the comparative data we need to evaluate therapeutic options.
Le texte complet de cet article est disponible en PDF.Key words : comparative effectiveness studies, dermatology, drug trials, economics, health policy, office dispensing, prescribing, sampling
Funding sources: None. |
|
Disclosure: Dr Resneck serves as the Chair of the Council on Government Affairs, Health Policy, and Practice of the American Academy of Dermatology Association, and Dr VanBeek serves as the Chair of the Academy’s Congressional Policy Committee, but this commentary reflects their personal views and not necessarily those of the American Academy of Dermatology Association. Neither of the authors’ clinics provide free samples of prescription medications to patients at this time. |
|
Reprints not available from the authors. |
Vol 62 - N° 6
P. 1062-1063 - juin 2010 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?